Canada Post Corp Registered Pension Plan Has $5.44 Million Holdings in Quest Diagnostics Incorporated $DGX

Canada Post Corp Registered Pension Plan boosted its position in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 131.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,800 shares of the medical research company’s stock after acquiring an additional 16,365 shares during the period. Canada Post Corp Registered Pension Plan’s holdings in Quest Diagnostics were worth $5,439,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in DGX. Perigon Wealth Management LLC lifted its position in shares of Quest Diagnostics by 4.5% during the 3rd quarter. Perigon Wealth Management LLC now owns 1,275 shares of the medical research company’s stock worth $243,000 after purchasing an additional 55 shares during the last quarter. Independent Advisor Alliance increased its position in Quest Diagnostics by 1.4% in the 3rd quarter. Independent Advisor Alliance now owns 4,232 shares of the medical research company’s stock worth $807,000 after buying an additional 59 shares during the period. True North Advisors LLC lifted its holdings in shares of Quest Diagnostics by 4.1% during the third quarter. True North Advisors LLC now owns 1,554 shares of the medical research company’s stock worth $296,000 after buying an additional 61 shares during the last quarter. OLD Second National Bank of Aurora boosted its position in shares of Quest Diagnostics by 14.9% in the third quarter. OLD Second National Bank of Aurora now owns 517 shares of the medical research company’s stock valued at $99,000 after acquiring an additional 67 shares during the period. Finally, World Investment Advisors grew its stake in shares of Quest Diagnostics by 2.7% in the second quarter. World Investment Advisors now owns 2,623 shares of the medical research company’s stock worth $471,000 after acquiring an additional 68 shares during the last quarter. 88.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on DGX. Jefferies Financial Group upped their target price on shares of Quest Diagnostics from $200.00 to $215.00 and gave the company a “buy” rating in a research note on Tuesday, October 21st. Truist Financial upped their price objective on shares of Quest Diagnostics from $195.00 to $205.00 and gave the company a “hold” rating in a research report on Wednesday, October 22nd. Leerink Partners increased their target price on shares of Quest Diagnostics from $203.00 to $210.00 and gave the company an “outperform” rating in a research note on Tuesday, October 21st. Weiss Ratings restated a “buy (b-)” rating on shares of Quest Diagnostics in a research note on Monday, December 29th. Finally, Morgan Stanley set a $207.00 price objective on Quest Diagnostics and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Eight research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, Quest Diagnostics currently has a consensus rating of “Moderate Buy” and an average price target of $198.50.

Quest Diagnostics Stock Performance

NYSE:DGX opened at $190.82 on Friday. The firm has a market capitalization of $21.23 billion, a PE ratio of 22.40, a price-to-earnings-growth ratio of 2.44 and a beta of 0.66. The company has a quick ratio of 1.04, a current ratio of 1.13 and a debt-to-equity ratio of 0.71. Quest Diagnostics Incorporated has a 12-month low of $157.20 and a 12-month high of $197.55. The firm has a 50-day moving average price of $181.18 and a 200 day moving average price of $181.27.

Quest Diagnostics Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, January 28th. Investors of record on Tuesday, January 13th were given a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 1.7%. The ex-dividend date was Tuesday, January 13th. Quest Diagnostics’s dividend payout ratio (DPR) is 37.56%.

Insider Activity at Quest Diagnostics

In related news, SVP Mark E. Delaney sold 7,946 shares of the business’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $187.35, for a total value of $1,488,683.10. Following the sale, the senior vice president owned 7,530 shares of the company’s stock, valued at $1,410,745.50. The trade was a 51.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO J. E. Davis sold 55,093 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $192.22, for a total value of $10,589,976.46. Following the transaction, the chief executive officer owned 120,480 shares of the company’s stock, valued at $23,158,665.60. This represents a 31.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 64,289 shares of company stock valued at $12,318,360 in the last 90 days. 8.16% of the stock is owned by corporate insiders.

Quest Diagnostics Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.